Akesson-Johansson A, Lernestedt J O, Ringdén O, Lönnqvist B, Wahren B
Department of Virology, National Bacteriological Laboratory, Stockholm, Sweden.
Bone Marrow Transplant. 1986 Dec;1(2):215-20.
Intravenous foscarnet was given on an emergency basis to 30 immunosuppressed patients with cytomegalovirus (CMV) disease, of whom 28 were organ transplant recipients. Thirteen patients responded to foscarnet by cessation of CMV secretion. The in vitro sensitivity to foscarnet of the CMV isolates from non-responders before, during and after foscarnet treatment was similar to that of viral isolates from responders before or during foscarnet treatment and also to CMV isolates from non-treated patients, with mean in vitro IC50 values of 239-294 microM of foscarnet. Thus, there was no evidence of increased resistance of the CMV isolates obtained after foscarnet treatment. A higher total foscarnet dose appeared to favor response.
对30例患有巨细胞病毒（CMV）疾病的免疫抑制患者进行了紧急静脉注射膦甲酸钠治疗，其中28例为器官移植受者。13例患者通过停止CMV分泌对膦甲酸钠产生反应。在膦甲酸钠治疗前、治疗期间和治疗后，无反应者的CMV分离株对膦甲酸钠的体外敏感性与反应者在膦甲酸钠治疗前或治疗期间的病毒分离株以及未治疗患者的CMV分离株相似，膦甲酸钠的平均体外IC50值为239 - 294 microM。因此，没有证据表明膦甲酸钠治疗后获得的CMV分离株耐药性增加。较高的膦甲酸钠总剂量似乎有利于产生反应。
